G02How clinical characteristics of recurrent/metastatic salivary gland malignancies (RMSGM) treated with first line chemotherapy (CT) impact on survival: multivariate analysis of 108 cases

Background: The role of CT for RMSGM is palliative only. In this abstract we report multivariate analysis of clinical characteristcs impact on survival.Material and methods: We enrolled 108 patients. Five patients received cisplatin (DDP) 100 mg/sm d1,q 3wks; 8 patients doxorubicin 75 mg/sm d1, q 3wks; 30 patients vinorelbine (VNB) 30 mg/sm d.1,8, q 3wks; 9 patients DDP+ epirubicin 60 mg/sm + 5-FU 600 mg/sm d.1, q 3wks; 42 patients DDP 80 mg/sm d.1 +VNB 25 mg/sm d.1,8, q 3wks and 14 patients carboplatin AUC 5.5. + paclitaxel 175 mg/sm d.1, q 3wks.Results: Patients characteristics were as follows: 64 males (59%) and 44 females (41%); median age: 57 years (20-74); 42 patients (39%) had ECOG PS 0 (47%) and 66 PS1-2 (61%); histology: adenocarcinoma (AC) 32 (30%), adenoid cystic cacinoma (ACC) 59 (55%), undifferentiated carcinoma (UC) 12 patients (11%) and malignant mixed tumor (MMT) 5 (4%); site of disease: local 41 (38%), mts + local 29 (27%), mts only 38 (35%). Responses: 3 CR, 24 PR, 36 NC and 45 PD; clinical benefit: PolyCT vs Mono CT : 63% vs 51%; DDP based vs NoDDP (64% vs 47%). Median TTP was 3.25 months and OS was 8.33 months.Table: G02Crude and Adjusted Hazards Ratios for MortalityVariablesUnadjusted Hazrd Ratio (UHR)UHR IC 95%UHR P-valueAdjusted Hazard Ratio (AHR)AHR IC 95%UHR P-valuePlatinum-based agentsno1-1-yes0.960.65-1.430.841.170-75-1.840.49Performance Status01-1-1-22.541.68-3.83<0.012.811.78-4.44<0.01HistologyAdenocarcinoma1-1-Adenoid cystic carcinoma1.300.84-2.010.241.660.98-2.80.06Undifferential carcinoma3.771.88-7.58<0.013.231.49-6.97<0.01Malignat mixed4.261.60-11.38<0.016.992.38-20.49<0.01MetastasisAbsent1-1-Present1.410.95-2.100.090.90.52-1.540.7 Open table in a new tab Background: The role of CT for RMSGM is palliative only. In this abstract we report multivariate analysis of clinical characteristcs impact on survival. Material and methods: We enrolled 108 patients. Five patients received cisplatin (DDP) 100 mg/sm d1,q 3wks; 8 patients doxorubicin 75 mg/sm d1, q 3wks; 30 patients vinorelbine (VNB) 30 mg/sm d.1,8, q 3wks; 9 patients DDP+ epirubicin 60 mg/sm + 5-FU 600 mg/sm d.1, q 3wks; 42 patients DDP 80 mg/sm d.1 +VNB 25 mg/sm d.1,8, q 3wks and 14 patients carboplatin AUC 5.5. + paclitaxel 175 mg/sm d.1, q 3wks. Results: Patients characteristics were as follows: 64 males (59%) and 44 females (41%); median age: 57 years (20-74); 42 patients (39%) had ECOG PS 0 (47%) and 66 PS1-2 (61%); histology: adenocarcinoma (AC) 32 (30%), adenoid cystic cacinoma (ACC) 59 (55%), undifferentiated carcinoma (UC) 12 patients (11%) and malignant mixed tumor (MMT) 5 (4%); site of disease: local 41 (38%), mts + local 29 (27%), mts only 38 (35%). Responses: 3 CR, 24 PR, 36 NC and 45 PD; clinical benefit: PolyCT vs Mono CT : 63% vs 51%; DDP based vs NoDDP (64% vs 47%). Median TTP was 3.25 months and OS was 8.33 months.